A Study to Assess Efficacy and Safety of RESP301 Plus Standard of Care (SOC) Compared to SOC Alone in Hospitalized Participants With COVID-19

• Status: Recruiting
• Trial end date: 2021-04-23
• Target enrollment: 0
• Participant gender: All

Summary

The effect of RESP301 as an add on treatment to SOC will be evaluated for its efficacy in reducing rate of progression to a more severe level of COVID-19 and for safety, by comparison with SOC alone in hospitalized COVID-19 patients.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Thirty Respiratory Limited
• Treatments: Nitric Oxide

Criteria

Inclusion Criteria:

1. Participant has laboratory-confirmed SARS-CoV-2 infection as determined by reverse transcriptase polymerase chain reaction (RT-PCR) or other approved clinical testing prior to randomization.

2. Participant is hospitalized in relation to COVID-19, requiring supplemental oxygen to maintain SpO2 at a safe level (WHO level 3 & 4).

3. Participant is capable of giving signed informed consent

4. Participant is male or female. All females of childbearing potential, including pregnant females, must consent to urine pregnancy testing at screening to be eligible for the study.

Exclusion Criteria:

1. Rapidly deteriorating or likely to require escalation to high flow oxygen, invasive or non-invasive ventilatory support within 24 hours according to Investigator's opinion.

2. Unable to safely receive a nebulized treatment for approximately 8 minutes according to Investigator's opinion.

3. Unable to receive or considered ineligible for invasive or non-invasive ventilatory support.

4. History of methemoglobinemia.

5. Presence of uncontrolled asthma, history of severe bronchospasm.

6. Presence of severe chronic respiratory disease and tracheostomy.

7. Suspected or confirmed untreated, active tuberculosis.

8. Severely immune-compromised participants in Investigator's opinion.

9. Recent active coronary artery disease or decompensated heart failure.